Company intelligence / Profile preview

Rigi Orphan

Baar, Zug, Switzerland

Ownership: Private
Development stage: Other

Overview

Rigi Orphan is a Swiss-based biotechnology and consulting firm specializing in the development and commercialization of orphan drugs for rare diseases. The company provides strategic advisory services and operational support to help international biotech firms navigate the complex regulatory and market access landscape in Europe and Switzerland. Rigi Orphan focuses on bridging the gap between innovative therapies and patients with high unmet medical needs by managing the entire lifecycle of orphan products. Their expertise spans regulatory affairs, pricing and reimbursement, and distribution logistics for specialized medicines.

Therapeutic areas: Rare Diseases
Modalities: Small moleculeBiologic
Industry: Consulting

Beyond the preview

Go deeper on Rigi Orphan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rigi Orphan.

Explore the full profile